Subscribe
Home
Issues
Online First
Latest Issue
Issue Archive
Special Issues
Browse By Topic
Personalized Medicine
Economics & Value
FDA Approvals, News & Updates
COVID-19
Cholangiocarcinoma
View All Topics ›
Conference Correspondent
SABCS 2023 - HER2+ MBC
ASCO 2023 - Breast Cancer
Web Exclusives
Web Exclusive Articles
Videos
Interview with the Innovators
Prostate Cancer Diagnostics Monthly Minutes
Webinars
Quick Quizzes
Press Releases
AVBCC
Association for Value-Based Cancer Care
VBCM
Value-Based Care in Myeloma
Issues
2011
October 2011, Vol 2, No 6
October 2011, Vol 2, No 6
PARP Inhibitor Olaparib a Promising Treatment for Ovarian Cancer
In the Literature
October 2011, Vol 2, No 6
In phase 1 and 2 clinical trials, olaparib, a small-molecule poly(ADPribose) polymerase (PARP) inhibitor, has demonstrated objective responses in women with breast or ovarian cancer and BRCA1 and BRCA2 mutations.
Read Article
AACR Urges Congress to Increase Funding for the NIH and NCI
Health Policy
,
Policies & Guidelines
October 2011, Vol 2, No 6
In September 2011, the American Association of Cancer Research (AACR) issued a new report, “AACR Cancer Progress Report 2011” on the current state of cancer research and the implications of recent cuts in funding for the National Institutes of Health (NIH) and the National Cancer Institute (NCI).
Read Article
US Preventive Services Task Force and the Future of Prostate Cancer Screening
By
Ross D. Margulies, JD, MPH
;
Jayson Slotnik, JD, MPH
Health Policy
,
Policies & Guidelines
October 2011, Vol 2, No 6
The decision this month (October 2011) by the US Preventive Services Task Force (USPSTF) to recommend against a prostate-specific antigen (PSA)-based screening for prostate cancer in healthy men
1
has caused quite a stir both in and outside of medical circles, reminding many people of the task force’s 2009 recommendation against routine breast cancer screenings for women under age 50 years.
Read Article
Progress in Molecular Markers that Predict Prognosis in AML
By
Phoebe Starr
NCCN Hematology Congress
October 2011, Vol 2, No 6
New York, NY—The era of personalized medicine is progressing. At the Fred Hutchinson Cancer Center, Seattle, WA, and at other centers, patients with intermediate-risk acute myeloid leukemia (AML) are now being tested for 3 molecular markers that predict prognosis.
Read Article
Advances in the Management of Chronic Lymphocytic Leukemia
By
Phoebe Starr
NCCN Hematology Congress
October 2011, Vol 2, No 6
New York, NY—Several advances have been made in the diagnosis and treatment of chronic lymphocytic leukemia (CLL), according to Susan O’Brien, MD, Chief, Acute Leukemia Section at M.D. Anderson Cancer Center, Houston.
Read Article
New Indications for Denosumab for Increasing Bone Density in Patients with Cancer
FDA Approvals, News & Updates
October 2011, Vol 2, No 6
The FDA approved 2 new indications for denosumab (Prolia, Amgen) for treating patients at high risk for therapy-induced bone fracture.
Read Article
ODAC Recommends Accelerated Approval for Iron Chelator Deferiprone
FDA Approvals, News & Updates
October 2011, Vol 2, No 6
Read Article
Genetic Diagnostic for ALK-Positive Status
FDA Approvals, News & Updates
October 2011, Vol 2, No 6
Read Article
Treatment Delay Feasible in Asymptomatic Follicular Lymphoma
By
Phoebe Starr
NCCN Hematology Congress
October 2011, Vol 2, No 6
New York, NY—Evidence suggests that maintenance therapy, as well as initiation of therapy for newly diagnosed follicular lymphoma, can be delayed in asymptomatic patients with low tumor burden, according to Andrew Zelenetz, MD, Chief of Lymphoma Service, Memorial Sloan-Kettering Cancer Center, New York, NY.
Read Article
The New Era of Personalized Medicine in Oncology: Novel Biomarkers Ushering in New Approaches to Cancer Therapy
By
Steve Stricker, PharmD, MS, BCOP
Value-Based Care
,
VBCC Perspectives
October 2011, Vol 2, No 6
It is next to impossible for a day to go by without thinking about the contributions of personalized medicine to the care of patients living with cancer. Whether we are treating a newly diagnosed patient with HER2/neupositive breast cancer using trastuzumab, or using erlotinib in the management of a patient with non–small-cell lung cancer (NSCLC) whose tumor harbors specific mutations in the epidermal growth factor receptor genes, individualizing therapy based on molecular biology and genetic testing has become commonplace in contemporary oncology practice.
Read Article
Page 2 of 4
1
2
3
4
View the Latest Issue of VBCC
Read Issue
Top Trending Articles
1.
Navigating the Complex Landscape of Oral Cancer Medication
2.
Luspatercept Yields Improved Transfusion Independence Compared With Epoetin Alfa in Patients With Lower-Risk MDS
Phoebe Starr
3.
New NCCN Guidelines for CLL/SLL Include Second-Generation BTK Inhibitors
Wayne Kuznar
Home
Issues
Online First
Latest Issue
Issue Archive
Special Issues
Browse By Topic
Personalized Medicine
Economics & Value
FDA Approvals, News & Updates
COVID-19
Cholangiocarcinoma
View All Topics ›
Conference Correspondent
SABCS 2023 - HER2+ MBC
ASCO 2023 - Breast Cancer
Web Exclusives
Web Exclusive Articles
Videos
Interview with the Innovators
Prostate Cancer Diagnostics Monthly Minutes
Webinars
Quick Quizzes
Press Releases
AVBCC
Association for Value-Based Cancer Care
VBCM
Value-Based Care in Myeloma